Skip to main content

Arvinas, Inc.

ARVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001655759

No open-market purchases or sales by Arvinas, Inc. insiders were filed in the last 90 days; 201 institutions reported holding it in 13F filings for Q2 2026, worth $476.6M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Arvinas, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Arvinas, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Arvinas, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Norwalk Leslie VDirector41,572Jun 26, 20261
Cunningham EverettDirector41,572Jun 26, 20261
Bain LindaDirector41,572Jun 26, 20261
Smaldone Alsup LaurieDirector41,572Jun 26, 20261
Morrison BriggsDirector111,548Jun 26, 20262
Kennedy Edward Moore Jr.Director54,957Jun 26, 20261
Saik AndrewChief Financial Officer187,432Jun 24, 20264
Cacace Angela MChief Scientific Officer180,390Jun 18, 20265
Teel RandyPresident and CEO285,009May 22, 20265
Berkowitz NoahChief Medical Officer191,395May 13, 20264
Loomis David KVP, Chief Accounting Officer40,193May 13, 20265
Houston John GDirector1,122,183Mar 2, 20261
Agarwal SunilDirector30,166Jun 30, 20250
Young John DDirector26,045Jun 27, 20250
Taylor IanPresident, R&D159,121Feb 25, 20250
Cassidy Sean AChief Financial Officer181,916Feb 27, 20240
Peck RonaldChief Medical Officer67,516Feb 27, 20240
Dixon Wendy LDirector9,121Jun 20, 20230
Shannon Timothy MDirector1,653,128IndirectJun 21, 20220
Ratcliffe LiamDirector185,686IndirectJun 21, 20220
Margus Bradley AlbertDirector2,000IndirectJun 21, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 24, 2026 (view filing)Jun 24Same daySaik AndrewChief Financial OfficerSSale−5.70K$8.16−$46.5K−2.9%187.4K after10b5-1
Jun 18, 2026 (view filing)Jun 171 dayCacace Angela MChief Scientific OfficerSSale−2.58K$7.60−$19.6K−1.4%180.4K after10b5-1
May 22, 2026 (view filing)May 211 dayTeel RandyPresident and CEOSSale−2.21K$9.04−$20.0K−0.8%285.0K after
May 13, 2026 (view filing)May 112 daysSaik AndrewChief Financial OfficerSSale−11.1K$9.94−$110.7K−5.5%193.1K after
May 13, 2026 (view filing)May 112 daysLoomis David KVP, Chief Accounting OfficerSSale−1.92K$9.94−$19.1K−4.6%40.2K after
May 13, 2026 (view filing)May 112 daysCacace Angela MChief Scientific OfficerSSale−9.66K$9.94−$96.0K−5.0%183.0K after
May 13, 2026 (view filing)May 112 daysBerkowitz NoahChief Medical OfficerSSale−11.1K$9.94−$110.4K−5.5%191.4K after
May 13, 2026 (view filing)May 112 daysTeel RandyPresident and CEOSSale−9.66K$9.94−$96.0K−3.3%287.2K after
Mar 19, 2026 (view filing)Mar 181 dayBerkowitz NoahChief Medical OfficerSSale−6.43K$11.10−$71.4K−3.1%202.5K after
Mar 9, 2026 (view filing)Mar 63 daysMorrison BriggsDirectorPPurchase+20.0K$13.40+$268.0K+26.3%96.0K after
Mar 2, 2026 (view filing)Feb 273 daysHouston John GDirectorSSale−35.3K$13.21−$466.2K−3.0%1.12M after3 lots
Feb 25, 2026 (view filing)Feb 232 daysLoomis David KChief Accounting OfficerSSale−1.11K$12.16−$13.5K−3.6%29.7K after
Feb 25, 2026 (view filing)Feb 232 daysCacace Angela MChief Scientific OfficerSSale−3.61K$12.16−$43.9K−2.4%147.6K after2 lots
Feb 25, 2026 (view filing)Feb 232 daysTeel RandyPresident and CEOSSale−4.79K$12.16−$58.2K−3.1%149.7K after2 lots
Feb 18, 2026 (view filing)Feb 135 daysTeel RandyPresident and CEOSSale−4.40K$11.89−$52.4K−2.8%154.5K after
Feb 18, 2026 (view filing)Feb 135 daysSaik AndrewChief Financial OfficerSSale−5.13K$11.89−$61.0K−3.1%159.3K after
Feb 18, 2026 (view filing)Feb 135 daysCacace Angela MChief Scientific OfficerSSale−4.59K$11.89−$54.6K−2.9%151.2K after
Feb 18, 2026 (view filing)Feb 135 daysBerkowitz NoahChief Medical OfficerSSale−5.68K$11.89−$67.6K−3.4%163.9K after
Feb 18, 2026 (view filing)Feb 135 daysLoomis David KChief Accounting OfficerSSale−1.02K$11.89−$12.1K−3.2%30.8K after
Nov 7, 2025 (view filing)Nov 7Same dayLoomis David KChief Accounting OfficerSSale−230$9.89−$2.27K−0.7%31.7K after
Sep 24, 2025 (view filing)Sep 222 daysMorrison BriggsDirectorPPurchase+30.0K$7.57+$227.1K+65.2%76.0K after
Jun 24, 2025 (view filing)Jun 24Same daySaik AndrewChief Financial OfficerSSale−5.70K$7.61−$43.4K−3.4%164.4K after
Jun 18, 2025 (view filing)Jun 171 dayCacace Angela MChief Scientific OfficerSSale−2.58K$7.49−$19.3K−1.6%154.2K after
Mar 19, 2025 (view filing)Mar 181 dayBerkowitz NoahChief Medical OfficerSSale−8.66K$8.59−$74.4K−7.3%110.0K after
Feb 25, 2025 (view filing)Feb 241 dayLoomis David KChief Accounting OfficerSSale−1.21K$16.75−$20.3K−6.0%18.9K after
Feb 25, 2025 (view filing)Feb 241 dayCacace Angela MChief Scientific OfficerSSale−4.21K$16.70−$70.2K−4.1%97.2K after2 lots
Feb 25, 2025 (view filing)Feb 241 dayTaylor IanPresident, R&DSSale−9.02K$16.71−$150.8K−5.4%159.1K after2 lots
Feb 25, 2025 (view filing)Feb 241 dayHouston John GPresident and CEOSSale−31.3K$16.72−$523.9K−2.6%1.16M after2 lots
Nov 12, 2024 (view filing)Nov 8, 2023-Nov 7, 2024370 daysLateLoomis David KChief Accounting OfficerSSale−460$22.39−$10.3K−5.4%8.04K after2 lots
Feb 27, 2024 (view filing)Feb 234 daysHouston John GPresident and CEOSSale−5.20K$47.05−$244.5K−0.5%1.04M after
Feb 27, 2024 (view filing)Feb 234 daysCassidy Sean AChief Financial OfficerSSale−1.70K$47.05−$80.1K−0.9%181.9K after
Feb 27, 2024 (view filing)Feb 234 daysPeck RonaldChief Medical OfficerSSale−1.70K$47.05−$79.9K−2.5%67.5K after
Feb 27, 2024 (view filing)Feb 234 daysTaylor IanChief Scientific OfficerSSale−1.70K$47.05−$80.0K−1.1%147.5K after
Aug 14, 2023 (view filing)Aug 113 daysPeck RonaldChief Medical OfficerSSale−1.32K$24.39−$32.3K−4.2%30.0K after10b5-1
Mar 3, 2023 (view filing)Mar 12 daysTaylor IanChief Scientific OfficerSSale−1.05K$29.53−$31.0K−1.0%101.7K after
Mar 3, 2023 (view filing)Mar 12 daysHouston John GPresident and CEOSSale−5.88K$29.53−$173.6K−0.6%917.4K after
Mar 3, 2023 (view filing)Mar 12 daysCassidy Sean AChief Financial OfficerSSale−1.75K$29.53−$51.5K−0.9%183.6K after
Aug 16, 2022 (view filing)Aug 124 daysPeck RonaldChief Medical OfficerSSale−1.26K$54.84−$69.0K−13.4%8.15K afterAmended
Apr 18, 2022 (view filing)Apr 144 daysMorrison BriggsDirectorSSale−21.0K$66.44−$1.39M−51.2%20.0K after3 lots
Mar 15, 2022 (view filing)Mar 114 daysCassidy Sean AChief Financial OfficerSSale−15.0K$70.00−$1.05M−8.5%161.4K after
Mar 4, 2022 (view filing)Mar 4Same dayTaylor IanChief Scientific OfficerSSale−869$63.94−$55.6K−1.0%84.0K after
Mar 4, 2022 (view filing)Mar 4Same dayCassidy Sean AChief Financial OfficerSSale−1.59K$63.94−$101.9K−1.0%161.4K after
Mar 4, 2022 (view filing)Mar 4Same dayHouston John GPresident and CEOSSale−6.02K$63.94−$385.2K−0.7%843.8K after
Feb 17, 2022 (view filing)Feb 152 daysTaylor IanChief Scientific OfficerSSale−20.0K$73.02−$1.46M−20.3%78.6K after6 lots
Jan 19, 2022 (view filing)Jan 145 daysMorrison BriggsDirectorSSale−21.0K$65.55−$1.37M−45.9%24.7K after4 lots
Jan 4, 2022 (view filing)Dec 30, 20215 daysPeck RonaldChief Medical OfficerSSale−20.0K$80.61−$1.61M−78.7%5.40K after2 lots
Dec 21, 2021 (view filing)Dec 174 daysCassidy Sean AChief Financial OfficerSSale−15.0K$70.00−$1.05M−8.7%158.2K after
Dec 16, 2021 (view filing)Dec 14-162 daysRatcliffe LiamDirectorSSale−355.7K$67.00−$23.8M−65.7%185.7K after8 lots
Nov 17, 2021 (view filing)Nov 152 daysTaylor IanChief Scientific OfficerSSale−20.0K$84.04−$1.68M−20.3%78.6K after3 lots
Nov 15, 2021 (view filing)Nov 10-155 daysRatcliffe LiamDirectorSSale−134.3K$85.83−$11.5M−19.9%541.4K after13 lots